A previous work has shown that in gliomas, regulatory T cells secrete TGFB1 and thereby promote the NF-kB-IL6-STAT3 signaling axis, and IL6 receptor blockers have a potential therapeutic effect (Liu et al. 2021). This evidence concerns the gene TGFB1 and central nervous system cancer.